Last Updated : April 25, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Tremfya | guselkumab | Psoriatic arthritis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Tresiba | insulin degludec | Diabetes mellitus, Type 1 & 2 | Reimburse with clinical criteria and/or conditions | Complete | ||
| Tridural | Tramadol hydrochloride | Pain | Do not list | Complete | ||
| Trikafta | elexacaftor/tezacaftor/ivacaftor and ivacaftor | Cystic fibrosis, F508del CFTR mutation, 6 years and older | Reimburse with clinical criteria and/or conditions | Complete | ||
| Trikafta | elexacaftor / tezacaftor / ivacaftor and ivacaftor | Cystic fibrosis, F508del CFTR mutation | Reimburse with clinical criteria and/or conditions | Complete | ||
| Trikafta | elexacaftor/tezacaftor/ivacaftor and ivacaftor | Cystic fibrosis, F508del CFTR mutation, 2 years and older | Reimburse with clinical criteria and/or conditions | Complete | ||
| Trikafta | elexacaftor/tezacaftor/ivacaftor and ivacaftor | Cystic fibrosis, F508del or responsive CFTR mutation, 2 years and older | Active | |||
| Trintellix | Vortioxetine | Depression, major depressive disorder | Withdrawn | |||
| Trintellix | vortioxetine hydrobromide | Major depressive disorder (MDD), adults. | Reimburse with clinical criteria and/or conditions | Complete | ||
| Trisenox | Arsenic Trioxide | Acute Promyelocytic Leukemia | Reimburse | Complete |
Last Updated : April 25, 2024